Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
Earnings Data
Report Date
Apr 24, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.51Last Year’s EPS
-4.4Same Quarter Last Year
Based on 21 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 24, 2025
|% Change Since: -0.14%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call showed strong financial performance and successful product launches, which were slightly overshadowed by disappointing clinical trial results and challenges related to the regulatory environment and Medicare Part D redesign.Company Guidance
During the Bristol-Myers Squibb Company First Quarter 2025 Earnings Conference Call, the company provided updated guidance reflecting a strong performance in the first quarter. Total revenues for the quarter were approximately $11.2 billion, with a growth portfolio sales increase of about 18%, driven by key products such as the IO portfolio, Breyanzi, Reblozyl, and Camzyos. The company revised its full-year revenue guidance to a range of $45.8 billion to $46.8 billion, also increasing its non-GAAP EPS guidance to between $6.70 and $7. The gross margin guidance remained at approximately 72%, while operating expenses for the year are expected to be around $16 billion. The company also expects to realize $2 billion in annual cost savings by the end of 2027, with $1 billion in savings anticipated by the end of this year. Despite some setbacks in clinical trials, the company remains confident in its growth trajectory and continues to focus on strategic capital allocation, including business development opportunities.Strong Q1 Financial Performance
Total company revenues were approximately $11.2 billion, reflecting strong demand across the growth portfolio. Global sales of the growth portfolio increased approximately 18%.
Successful Product Launches
Cobenfi and OpdivoCuvanti are off to strong starts. Cobenfi sales were approximately $27 million, tracking ahead of all branded schizophrenia launch benchmarks.
Pipeline Advancements
Opdivo plus Yervoy received FDA and EMA approvals for first-line liver cancer. Breyanzi approved in the EU for follicular lymphoma. Camzyos received a favorable label update in the US.
Increased Financial Guidance
Full-year revenue guidance increased to a range of $45.8 billion to $46.8 billion, with non-GAAP EPS guidance raised to between $6.70 and $7.
Cost Management and Operational Efficiency
Operating expenses were more than $500 million lower compared to the same period last year. The company expects to realize approximately $2 billion in annual cost savings by the end of 2027.
---
BMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BMY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 24, 2025 | $48.53 | $48.69 | +0.33% |
| Feb 06, 2025 | $59.07 | $56.80 | -3.84% |
| Oct 31, 2024 | $51.53 | $54.57 | +5.90% |
| Jul 26, 2024 | $43.80 | $48.82 | +11.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bristol-Myers Squibb (BMY) report earnings?
Bristol-Myers Squibb (BMY) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
What is Bristol-Myers Squibb (BMY) earnings time?
Bristol-Myers Squibb (BMY) earnings time is at Apr 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BMY EPS forecast?
BMY EPS forecast for the fiscal quarter 2025 (Q1) is 1.51.
---
